AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward

Med411.com Medical Award

HealthAtoZ.com Featured Site Award

BuscaSalud.com

IBS Tales Hope Award

HealingWell.com Editor's Choice Award

Listed in Listed in Treasures of the Internet


AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Reviewed April 21, 2014

Fact Sheet 417

Combivir (zidovudine + lamivudine)


WHAT IS COMBIVIR?
WHO SHOULD TAKE COMBIVIR?
WHAT ABOUT DRUG RESISTANCE?
HOW IS COMBIVIR TAKEN?
WHAT ARE THE SIDE EFFECTS?
HOW DOES COMBIVIR REACT WITH OTHER DRUGS?
 


WHAT IS COMBIVIR?

Combivir is a pill that contains two drugs used as part of antiretroviral therapy (ART): zidovudine (Retrovir, AZT) and lamivudine (Epivir, 3TC). Combivir is manufactured by ViiV Healthcare.  Generic versions have been tentatively approved under PEPFAR (see fact sheet 925.) Lamivudine is also known as 3TC.

The drugs in Combivir are called nucleoside analog reverse transcriptase inhibitors, or nukes. These drugs block the reverse transcriptase enzyme. This enzyme changes HIV’s genetic material (RNA) into the form of DNA. This has to occur before HIV’s genetic code gets inserted into an infected cell’s own genetic codes.

 


WHO SHOULD TAKE COMBIVIR?

Combivir was approved in 1997 as an antiretroviral drug (ARV) for people with HIV infection. Combivir should not be used by children weighing less than 30 kg (about 66 pounds.)

Some people with HIV had their hepatitis B get worse after they stopped taking lamivudine, a part of Combivir. Get tested for hepatitis B before you start taking Combivir to treat HIV. If you have hepatitis B and stop taking Combivir, your health care provider should carefully monitor your liver function for several months.See Fact Sheet 506 for an overview on hepatitis.

There are no absolute rules about when to start ART. You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking ART. Fact Sheet 404 has more information about guidelines for the use of ART.

If you take Combivir with other ARVs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.

People with kidney problems should not take Combivir.

Combivir provides two drugs in one pill. It can be more convenient to use Combivir than some other combinations of drugs. This could mean fewer missed doses and better control of HIV.

 


WHAT ABOUT DRUG RESISTANCE?

Many new copies of HIV are mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance.”

Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.

 


HOW IS COMBIVIR TAKEN?

Combivir is taken by mouth as a tablet. The normal adult dose is one tablet, two times a day. Each tablet includes 300 milligrams (mg) of zidovudine (Retrovir, AZT) and 150 mg of lamivudine (Epivir, 3TC).

Combivir can be taken with food, or between meals.

The dosage of lamivudine should be reduced for people who weigh less than 50 kilograms (110 pounds). People who weigh less than 110 pounds should normally not take Combivir.

 


WHAT ARE THE SIDE EFFECTS?

When you start any ART, you may have temporary side effects such as headaches, high blood pressure, or a general sense of feeling ill. These side effects usually get better or disappear over time.

The most common side effects of Combivir are the same as with zidovudine (Retrovir) and lamivudine (Epivir). They include headache, upset stomach, and fatigue. See Fact Sheet 551 for more information on fatigue.

The most serious side effects of zidovudine are anemia, granulocytopenia, and myopathy. Very few people have these side effects. If they occur, your health care provider will probably have you stop using Combivir. See Fact Sheet 411 on zidovudine for more information on these side effects.

Anemia is a shortage of red blood cells caused by damage to bone marrow. Fact Sheet 552 has more information on anemia.

Granulocytopenia is a shortage of white blood cells caused by damage to bone marrow.

Myopathy is muscle pain and weakness. There is no specific treatment for myopathy.

 


HOW DOES COMBIVIR REACT WITH OTHER DRUGS?

Combivir can interact with other drugs or supplements you are taking. These interactions can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are constantly being identified. Make sure that your health care provider knows about ALL drugs and supplements you are taking.

Combivir should not be taken with stavudine (Zerit, d4T). Also, lamivudine and emtricitabine (FTC) are very similar and should not be taken together.

Blood levels of lamivudine may be increased by bactrim or septra. See Fact Sheet 535 for more information on these drugs.

Zidovudine’s side effects may be worse if you are taking several other drugs.

Methadone may increase blood levels of zidovudine. If you take Combivir and methadone, watch for zidovudine side effects.

 


 


Back to Fact Sheet Categories



New Mexico AIDS Education and Training Center The University of New Mexico Health Sciences Center International Association of Providers of AIDS Care

 

The AIDS InfoNet is a project of the New Mexico AIDS Education and Training Center at the University of New Mexico Health Sciences Center,
and the International Association of Providers of AIDS Care.
webmaster@aidsinfonet.org

 

United States National Library of Medicine

Partially funded by the National Library of Medicine



Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please provide your e-mail address below, and click on the "Submit" button.



Subscribe
Unsubscribe